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Abstract Background: The use of L-asparaginase (ASNase) to modify amino acid
metabolism is one of the most effective chemotherapeutic means of inducing
remission in acute lymphoblastic leukemia (ALL). However, severe pancre-
atitis sometimes occurs in patients receiving ASNase, because of an unknown
mechanism.
Objective: The purpose of the present study was to evaluate the relationship
between ASNase-induced pancreatic injury and plasma amino acid levels in
patients undergoing ASNase therapy.
Methods: A total of 29 children aged 1–13.25 years (median age 4 years;
male : female ratio 19 : 10) with ALL, who received induction therapy ac-
cording to the Tokyo Children’s Cancer Study Group L04-16 protocol, were
studied. Levels of plasma amino acids and serum rapid turnover proteins
(RTPs), pancreatic enzymes, and pancreatic protease inhibitors were meas-
ured before and 1, 2, 3, 4, 5, and 7 weeks after the first administration of
ASNase.
Results: Plasma asparagine levels were significantly lower after the first in-
jection of ASNase (p< 0.01) and had almost recovered 2 weeks after the last
ASNase injection. At 4 weeks after the first ASNase injection, serum aspartic
acid, trypsin, and pancreatic secretory trypsin inhibitor (PSTI) levels re-
mained significantly higher than those before the first ASNase injection
(p< 0.01), and serum levels of prealbumin and transferrin remained signif-
icantly lower than those before the first ASNase injection (p< 0.01). Plasma
amino acid and serum RTP levels gradually normalized after the last ASNase
injection.
Conclusions: Levels of serum trypsin and PSTI were elevated during the
2 weeks after administration of ASNase, which suggested the presence of
subclinical pancreatitis. This period is similar to the time period in the present
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study when the levels of plasma amino acids changed, thus suggesting that
ASNase-induced pancreatic injury could be caused by the imbalance of
plasma amino acid levels.
Introduction
L-asparaginase (ASNase) is an important onco-
therapy, particularly for acute lymphoblastic
leukemia (ALL). ASNase is thought to exert its
anti-tumor activity by hydrolyzing asparagine to
aspartate and ammonia. Asparagine synthetase
activity in some malignant lymphoblasts is very
low, and the lymphoblasts rely on an exogenous
supply of amino acids. Lymphoblasts thereby
deplete the supply of asparagine, which leads to
cell death.[1-3] An advantage of ASNase is that it
does not have cross-resistance with other anti-tumor
agents. Another important advantage is that it
has low toxicity in normal tissues and in other
neoplastic cells that express high levels of aspar-
agine synthetase. Potential side effects of ASNase
include hypersensitivity reactions, central nervous
system dysfunction, coagulation abnormalities,
liver dysfunction, hyperglycemia, hyperlipemia,
and pancreatitis.[4]
In some cases, ASNase-induced pancreatitis
can be life threatening and all chemotherapy must
be discontinued. Although patients can recover
from this kind of acute pancreatitis, re-initiation
of therapy with ASNase in such cases is gener-
ally considered contraindicated. There are vari-
ous treatments for ASNase-induced pancreatitis:
some reports have suggested use of octreotide[5-7]
or a continuous regional arterial infusion of a
protease inhibitor and antibiotics.[8] Although
pancreatitis remains one of the most severe com-
plications of ASNase therapy, it is impossible to
predict who will develop pancreatic toxicity from
ASNase.[9] Furthermore, there is no adequate
prophylaxis for this potentially life-threatening
condition.
In the present study, the pharmacologic effects
of ASNase on plasma amino acid levels and
serum rapid turnover protein (RTP) levels were
investigated as factors potentially related to
ASNase-induced pancreatic injury. The presence
of pancreatitis or pancreatic injury during admin-
istration of ASNase was evaluated through meas-
urement of the levels of serum pancreatic enzymes
and pancreatic protease inhibitors.
Methods
Subjects
The study group consisted of 29 children aged
1 year to 13.25 years (median age 4 years; male :
female ratio 19 : 10) who were newly diagnosed
with ALL and received chemotherapy for ALL
(B-cell phenotype : T-cell phenotype ratio 25 : 4).
Patients were classified as standard risk (SR) if
they met the following criteria: age 1–9.99 years
and white blood cell count <50 000/mL. All others
were designated as high risk (HR) [SR :HR ratio
18 : 11]. Induction therapy was initiated accord-
ing to the Tokyo Children’s Cancer Study Group
L04-16 protocol and consisted of prednisolone
60mg/m2/day (on days 1–35, tapering off on days
36–42); vincristine 1.5mg/m2/day (on days 8, 15,
22, 29, and 36); daunomycin 25mg/m2/day (on
days 10, 11, 31, and 32); ASNase derived from
Escherichia coli (Leunase; Kyowa Hakko Kirin,
Tokyo, Japan) 6000 IU/m2/day (on days 15, 17,
19, 22, 24, 26, 29, 31, and 33); cyclophosphamide
1 g/m2/day (on days 9 and 30); and intrathecal
administration of hydrocortisone sodium phos-
phate 25mg/day, methotrexate 12.5mg/day, and
cytarabine 25mg/day (on days 8 and 22) [figure 1].
The study protocol was approved by the ethics
committee of the Juntendo University School of
Medicine. Informed consent was obtained from
all patients or their parents before participation
in the study.
Samples
Blood samples were collected before the first
injection of ASNase (day 15) and at 1 week (day
22), 2 weeks (day 29), 3 weeks (day 36), 4 weeks
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(day 43), 5 weeks (day 50), and 7 weeks (day 64)
after the first injection of ASNase. Blood samples
were used for measurement of levels of serum
amylase, lipase, trypsin, pancreatic protease in-
hibitors (pancreatic secretory trypsin inhibitor
[PSTI], a1-antitrypsin [a1-AT], and a2-macro-
globulin [a2-M]), and RTPs (prealbumin [PA],
transferrin [Tf], and retinol-binding protein
[RBP]), and plasma amino acids. In the present
study, serum levels of RTPs were investigated as
products that are induced by metabolism of
plasma amino acids. After day 33, all patients
continued to receive other oncolytic agents but
did not receive ASNase during induction therapy.
Assays
Blood samples were divided into two groups.
One group was placed in heparinized tubes (Ni-
pro Co., Ltd., Tokyo, Japan) and immediately
centrifuged at 3000 rpm for 5 minutes at -4C.
Plasma was mixed with an equal volume of 10%
sulfosalicylic acid (w/v) under ice for rapid de-
proteinization and inactivation of ASNase.[10]
The mixture was centrifuged, and the supernatant
was used as the sample solution. Amino acid
analysis was performed with high-performance
liquid chromatography after precolumn deriva-
tion with o-phthaldialdehyde, as previously de-
scribed, using an L-8500 Amino Acid Analyzer
(Hitachi Co., Ltd., Tokyo, Japan).[11] Plasma amino
acid levels are expressed in nanomoles per milli-
liter (nmol/mL). Plasma amino acid levels were
measured twice to ensure accuracy.
The second group of blood samples was col-
lected in tubes containing a serum separating
agent and coagulation promotion film (Nipro
Co., Ltd., Osaka, Japan), and separation was per-
formed by centrifugation at 3000 rpm for 10 min-
utes at 22C. Serum levels of amylase and lipase
were measured in our institutional laboratory,
the accuracy of which was assured by the
Japanese Society of Laboratory Medicine. Re-
sults are expressed in international units per liter
(IU/L). Trypsin was measured by a radio-
immunoassay (RIA-Gnost Trypsin II Kit; Nihon
Schering Co., Ltd., Osaka, Japan). PSTI was
measured by a radioimmunoassay (Ab-Bead
PSTI Kit; Eiken Chemical Co., Ltd., Tokyo,
Japan). Trypsin and PSTI levels are expressed
in nanograms per milliliter (ng/mL). The levels of
a1-AT and a2-M were determined by the neph-
elometry method with a BN II Analyzer (Dade
Behring GmbH, Marburg, Germany). The re-
sults of both protein measurements are expressed
in milligrams per deciliter (mg/dL). The levels of
PA and RBP were measured by the nephelometry
method with a BN II Analyzer (Dade Behring
Co., Ltd., Tokyo, Japan). Serum Tf levels were
determined on a JCA-BM12 Biochemical Ana-
lyzer (Japan Electron Optics Laboratory Co.,
Ltd., Tokyo, Japan) with a turbidimetric im-
munoassay (N-Assay TIA Tf-H Nittobo; Nitto
Boseki Co., Ltd., Tokyo, Japan). The RTP levels
are expressed in milligrams per deciliter (mg/dL).
Serum pancreatic enzyme, pancreatic protease
inhibitor, and RTP levels were measured twice to
ensure accuracy.
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Fig. 1. Induction therapy regimen of the Tokyo Children’s Cancer Study Group L04-16 protocol. Blood samples were collected on days 15, 22,
29, 36, 43, 50, and 64. Patients received L-asparaginase 6000 IU/m2/day on days 15, 17, 19, 22, 24, 26, 29, 31, and 33. Patients received
prednisolone 60mg/m2/day on days 1–35, tapering off on days 36–42. Patients received vincristine 1.5mg/m2/day on days 8, 15, 22, 29, and
36. Patients received daunomycin 25mg/m2/day on days 10, 11, 31, and 32. Patients received cyclophosphamide 1 g/m2/day on days 9 and
30. A =L-asparaginase; B =blood; C = cyclophosphamide; D =daunomycin; V = vincristine.
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Statistics
Values are presented as the mean – standard
deviation (SD). Statistical analysis was performed
with the non-parametric Friedman test. SPSS
statistical analysis software (IBM SPSS Statis-
tics Version 19) was used for all computations. A
p-value of <0.05 was considered statistically
significant.
Results
One patient (a 1-year-old girl) developed
ASNase-induced pancreatitis. The results for the
rest of the cases (n = 28) were as follows.
Plasma Amino Acid Levels
Plasma asparagine levels after the first in-
jection of ASNase were significantly lower than
those before theASNase injection (p< 0.01). Plasma
asparagine reached minimum levels 2 weeks after
the first injection, gradually increased, and had
almost recovered at 5 weeks after the first in-
jection. Serum aspartic acid levels at 1, 2, 3, and
4 weeks after the first ASNase injection were
significantly higher than those before the ASNase
injection (p < 0.01). Levels of most of the other
amino acids fluctuated 1, 2, and 3 weeks after the
first injection, and there were almost no differ-
ences between the levels before the first ASNase
injection and those 5 and 7 weeks after the first
injection (table I).
Serum Rapid Turnover Protein Levels
Serum levels of RTPs rapidly decreased after
the first ASNase injection. Serum levels of PA
and Tf at 1, 2, 3, and 4 weeks after the first ASNase
injection were significantly lower than those be-
fore the first ASNase injection (p < 0.01). Serum
levels of RTPs reached minimum levels 2 weeks
after the first ASNase injection and then gradu-
ally increased (table II).
Serum Pancreatic Enzyme and Pancreatic
Protease Inhibitor Levels
Serum levels of amylase and lipase did not
fluctuate during the observation period. Serum
trypsin levels at 2, 3, and 4 weeks after the first
ASNase injection were significantly higher than
those before the first ASNase injection (p < 0.01).
Serum PSTI levels at 2, 3, and 4 weeks after the
first ASNase injection were also higher than
those before the first ASNase injection (p < 0.01).
Serum levels of a1-AT and a2-M remained un-
changed during ASNase therapy (table II).
The Patient Who Developed Pancreatitis
A 15-month-old girl who developed pancreatitis
experienced nausea and upper abdominal pain on
the day after the fourth ASNase injection (day 22).
Table I. Time course of plasma amino acid levels


















Aspartic acid 2.7 –2.2 8.4 – 4.7** 9.9 – 6.4** 12.6 – 9.5** 13.2 – 8.4** 6.1 –5.9 3.2 –3
Asparagine 46.2 – 13.9 2.3 – 8.0** 0– 0** 2.6 –7.7** 7.5 –15.3** 36.7 – 14.3** 37.1 – 8.6**
Glutamic acid 58.4 – 20.1 160.5 – 123.7** 160.4 –109.1** 190.1 –148.5** 90.3 – 46.0 69.0 – 23.3 50.0 – 14.0
Glutamine 453.8 –89.3 294.3 – 124.7** 295.9 –145.6** 294.9 –162.8** 380.2 –103.2** 462.8 – 107.9 464.6 –82.6
Threonine 124.6 –44.3 148.4 – 96.8 216.9 –96.8** 221.4 –110.0** 136.4 –69.2 106.9 – 46.6 103.8 –33.0
Cystine 37.2 – 10.0 33.5 –8.0 32.9 –8.7 32.2 – 10.5* 37.1 – 9.5 42.3 – 9.4 40.8 – 8.1*
Methionine 22.4 – 7.8 20.3 –6.7 22.9 –8.3 24.3 – 9.2 18.1 – 7.5 20.6 – 6.9 19.0 – 5.4
Lysine 189.1 –58.1 137.1 – 42.3** 138.5 –39.1** 168.7 –76.5 156.7 –57.5* 160.7 – 52.3* 154.3 –42.2*
Arginine 75.4 – 34.7 48.8 –21.9** 51.4 –21.4** 63.3 – 30.0* 57.1 – 23.4** 60.7 – 33.5* 56.2 – 22.7**
Citrulline 17.6 – 7.0 18.2 –6.8 19.9 –8.7 19.4 – 9.0 17.8 – 7.7 20.2 – 4.8 16.5 – 6.3
ASNase =L-asparaginase; * p< 0.05, ** p< 0.01 versus levels before the ASNase injection.
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She was diagnosed as having ASNase-induced
pancreatitis by elevated levels of serum pancreatic
enzymes and findings of abdominal computed to-
mography. Her serum PSTI level was also higher
than that before the first ASNase injection, and her
serum levels of a1-AT and a2-M remained un-
changed on that day (day 22). Changes in her
serum amino acid levels between day 15 and day 22
were similar to the results in patients who did not
develop acute pancreatitis. Though she recovered
from the pancreatitis after 2 weeks of conservative
therapy, it was deemed unsafe to use ASNase with
the rest of her oncotherapy, for fear of recurrent
pancreatitis.
Discussion
Because of use of other chemotherapeutic
agents (including steroids) during oncotherapy,
the mechanisms of ASNase-induced pancreatitis
in humans remain unknown. Although there
have been many reports of ASNase-induced pan-
creatitis,[6,9,12-16] few studies have examined the
relationship between ASNase therapy and acute
pancreatitis by measuring changes in serum levels
of pancreatic enzymes or plasma levels of amino
acids.[15,17,18] As in previous studies,[19,20] in the
present study the plasma asparagine levels de-
creased rapidly after the first ASNase injection.
On the other hand, the levels of plasma aspartic
acid increased. By 4 weeks after the first injection
of ASNase, these changes had gradually normal-
ized, and almost normal levels of asparagine and
aspartic acid were seen 5 weeks after the first in-
jection of ASNase. Levels of other amino acids
changed during the first week after the injection
of ASNase and recovered 4 weeks after the first
injection of ASNase. These results suggest that it
takes about 2 weeks for the imbalance of plasma
amino acid levels after the last injection of ASNase
to improve.
RTP levels in the serum rapidly decreased after
the first ASNase injection and gradually nor-
malized during the 4 weeks after the first in-
jection. These changes suggest that the imbalance
of plasma amino acids prevents intracellular
utilization of amino acids, and a decrease in RTP
levels could be a result of this imbalance. Not
only administration of ASNase during chemo-
therapy but also other therapeutic drugs and
anorexia have been implicated as factors capable
of inducing these changes. However, the present
results indicate that levels of plasma amino acids
and serum RTPs gradually normalize after the
last ASNase injection, despite continued use of
other chemotherapeutic drugs.
Serum amylase and lipase levels were un-
changed during the present study, though serum


















Amylase (IU/L) 60.6 –27.6 56.0 –28.5 55.3 – 25.4 52.1 – 21.3 51.4 – 22.5 55.2 –22.2 55.7 –39.1
Lipase (IU/L) 18.7 –8.2 16.2 –4.6 19.1 – 8.9 20.7 – 9.0 21.3 – 6.4 23.8 –8.1 29.2 –35.7
Trypsin (ng/mL) 285.7 –142.3 326.5 –131.2 330– 133.5** 371.3 – 157.5** 362.2 – 202.9** 306.4 –170.2 324.1 –470.4
Pancreatic protease inhibitors
PSTI (ng/mL) 10.7 –4.9 35.7 –24.8 83.1 – 83.6** 74.9 – 47.8** 53.3 – 48.3** 12.2 –7.0 13.2 –10.0
a1-AT (mg/dL) 139.3 –43.3 120 –33.8 113.5 – 31.5 131.6 – 48.6 168.6 – 50.2** 145.6 –54.8 148.7 –40.5
a2-M (mg/dL) 271.1 –45.4 263.0 –51.8 250.3 – 42.7 265.5 – 55.8 302.1 – 69.8 354.0 –60.4** 346.5 –75.7**
Rapid turnover proteins
PA (mg/dL) 33.8 –7.8 23.0 –7.0** 18.7 – 7.2** 25.3 – 11.4** 26.8 – 11.4** 22.3 –7.0** 23.5 –8.1**
RBP (mg/dL) 4.3 –1.0 3.1 –1.2** 2.6 – 1.0** 4.3 – 4.4** 4.2 – 2.0 3.2 –0.9** 3.4 –1.3**
Tf (mg/dL) 233.3 –46.4 164.9 –40.3** 120.7 – 34.5** 120.7 – 41.2** 154.2 – 50.0** 208.1 –30.8** 172.6 –24.1**
a1-AT =a1-antitrypsin; a2-M = a2-macroglobulin; ASNase =L-asparaginase; PA = prealbumin; PSTI =pancreatic secretory trypsin inhibitor;
RBP = retinol-binding protein; Tf = transferrin; * p< 0.05, ** p< 0.01 versus levels before the ASNase injection.
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trypsin levels increased after the ASNase in-
jection. Serum PSTI levels increased after the
ASNase injection as well. Acute pancreatitis de-
velops with unregulated trypsin activity after
breakdown of critical protective mechanisms and
copious secretion of pancreatic enzymes such as
amylase and lipase.[21,22] The present results in-
dicate that inhibitors of trypsin could potentially
prevent development of pancreatitis, and sug-
gest the presence of subclinical pancreatitis in
cases who do not develop pancreatitis during
administration of ASNase. Not only ASNase but
also prednisolone has been implicated as an agent
capable of inducing pancreatitis.[23] Previous re-
ports suggest that ASNase is the more likely source
of pancreatitis on the basis of histologic examina-
tion of the pancreas, the relative infrequency of
prednisolone-induced pancreatitis, and a negative
result after rechallenge with prednisolone.[14,18,24]
In the present study, one of 29 patients (3%)
developed ASNase-induced pancreatitis, similar
to the morbidity rates in previous reports.[4,6,9,16,25]
Since the patient developed severe pancreatitis,
ASNase was contraindicated during the rest of
her treatment for ALL. The results of her blood
tests were similar to the results from those pa-
tients who did not develop acute pancreatitis, so
there was no parameter that could be used to predict
acute pancreatitis. When ASNase-induced pan-
creatitis occurs, treatment with Erwinia chrys-
anthemi asparaginase is an option. As it can also
lead to pancreatitis, Erwinia asparaginase is a
second-line therapy for ALL after hypersensi-
tivity to Escherichia coli asparaginase.[26] Fur-
thermore, there are no widely accepted guidelines
for use of Erwinia asparaginase, and such treat-
ment is not covered by health insurance providers
in Japan. Previous reports have shown that there
is a mean of almost 10 days from the last adminis-
tration of ASNase to diagnosis of pancreatitis.[5,9,16]
Similarly, Japanese case reports of ASNase-
induced pancreatitis have shown that 50 of 56
patients (89%) who developed ASNase-induced
pancreatitis did so within 10 days (median 2 days,
range 0–23 days) after administration of AS-
Nase.[27] This period is similar to the time period
in the present studywhen the levels of plasma amino
acids, serum trypsin, and serum PSTI changed.
In the rat model, it has been proposed that ASN-
ase-induced pancreatic injury can involve disrup-
tion of the plasma amino acid balance that is caused
by ASNase. Disruption of protein synthesis in aci-
nar cells then causes inhibition of exocytosis fol-
lowing the histologic morphologic changes.[28] The
present results imply that the plasma amino acid
level imbalance could also be a factor in ASNase-
induced pancreatitis in humans. In clinical cases,
there would also be other triggers of pancreatitis in
addition to the plasma amino acid level imbalance.
Though there is no well established prophy-
laxis for ASNase-induced pancreatic injury, it has
been reported that an ALL patient was success-
fully retreated using ASNase with octreotide after
an episode of ASNase-induced pancreatitis.[29,30]
Octreotide is capable of inhibiting pancreatic up-
take of plasma amino acids, and this inhibition
could be an important mechanism by which oc-
treotide decreases pancreatic enzyme secretion.[31]
It is thought that octreotide could prevent ASNase-
induced pancreatic injury through its physiopa-
thologic properties. Recently, Muwakkit et al. have
also suggested that allopurinol, which is an inhi-
bitor of xanthine oxidase, has a preventive effect
on ASNase-induced pancreatitis.[32]
Conclusion
An imbalance of plasma amino acid levels
during the 2 weeks after administration ofASNase
was observed. In this period, elevations of serum
trypsin and PSTI levels were also observed,
indicating the possible presence of subclinical
pancreatitis in the patients who did not develop
pancreatitis. This imbalance of plasma amino acid
levels normalized after ASNase was discontinued,
even though other chemotherapy for ALL con-
tinued. This plasma amino acid imbalance could
be one factor behind ASNase-induced pancreatitis
and pancreatic injury in humans. Further research
should focus on prophylaxis for ASNase-induced
pancreatic injury, which could greatly improve
treatment outcomes of ALL in children.
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